MICRO-CT IMAGING OF AVASTIN-TREATED MICE WITH LS174TT TUMORS

该子项目是利用资源的许多研究子项目之一 由NIH/NCRR资助的中心拨款提供。次级项目的主要支助 子项目的主要研究者可能是由其他来源提供的， 包括其他NIH来源。 为子项目列出的总成本可能 表示子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 目的：研究安维汀治疗后血管正常化的假说。我们将使用Isovue 370的动态微CT来可视化灌注，使用脂质体造影剂的静态微CT来可视化肿瘤中的渗透性。将于2010年1月5日将12只具有存活肿瘤的动物从皮埃蒙特研究中心转移至杜克。6只小鼠将用安维汀处理，6只小鼠将作为对照。治疗包括每两周一次IP给予5 mg/kg安维汀，并将在：1月7日星期四开始的星期四和星期一进行。 第一个成像日将是1月8日星期五。 4个治疗组： 1)对照脂质体，3只动物（CL） 2)对照灌注，3只动物（CP） 3)给药脂质体，3只动物（TL） 4)处理灌注，3只动物（TP） CL组和TL组将于周一通过尾静脉注射脂质体造影剂（0.3 ml/25 g小鼠），每周周一（0小时）和周三（48小时）进行静态显微CT成像。 CP组和TP组将在周五使用动态显微CT每周进行一次成像，以比较灌注。对于这些研究，我们将使用尾静脉导管以0.5ml/25 g小鼠的剂量递送Isovue 370。动物将在每次成像后恢复。我们预计未处理的小鼠（CL，CP）将达到终点，此时它们将需要在1月5日开始的第0天的约17天内被处死。给药动物（TL、TP）将在约36天内达到终点。因此，将仅对组（CP、CP）中的6只动物进行2周成像。对于未治疗的动物，成像可持续长达5周。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Aim: Study the hypothesis of vascular normalization as a result of Avastin treatment. We will use both dynamic micro-CT with a Isovue 370 to visualize perfusion and static micro-CT with a liposomal contrast agent to visualize permeability in tumors. 12 animals with viable tumors will be transfered from Piedmont Research Center to Duke on 1-5-10. 6 mice will be treated with Avastin and 6 mice will be controls. Treatment involves 5mg/kg of Avastin given IP biweekly, and will take place on: Thursdays and Mondays starting on Thursday January 7th. The first imaging day will be Friday January 8th. 4 treatment groups: 1) Control Liposome, 3 animals (CL) 2) Control Perfusion, 3 animals (CP) 3) Treated Liposome, 3 animals ( TL) 4) Treated Perfusion, 3 animals (TP) The groups CL and TL will be injected via tail vein with liposomal contrast ( 0.3 ml/25g mouse) on Mondays and static micro-CT imaging will take place on Mondays (0 hours) and Wednesdays (48hours) every week. The groups CP and TP will be imaged once per week on Fridays using dynamic micro-CT to compare perfusion. For these stusdies we will use a tail vein catheter to deliver Isovue 370 in a dose of 0.5ml/25 g mouse). Animals will be recovered after each imaging session. We expect that untreated mice (CL, CP) will reach the end point when they will need to be sacrificed in about 17 days with Day 0 starting on January 5th. The treated animals (TL, TP) will reach the endpoint in about 36 days. Therefore, imaging the 6 animals in groups (CP,CP) will take place for only 2 weeks. For untreated animals the imaging could last up to 5 weeks.